The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.

Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.

Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.

1. HIV is a Virus; AIDS is a Syndrome

HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.

AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.

2. Not Everyone with HIV Develops AIDS

A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.

Without treatment, however, HIV progresses through three stages:

- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.

- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.

- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.

3. HIV is Transmissible; AIDS is Not

Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.

AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.

4. Diagnosis Methods Differ

HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.

AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.

5. Treatment Goals Are Different

The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.

For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.

Role of Community Engagement in Combatting HIV/AIDS

While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."

Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.

The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.

Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.

The ovaries are a pair of pelvic organs in biological females associated with reproduction. Cancer of the ovaries is unfortunately increasing in incidence and usually presents late in the course of the disease. Ovarian cancer is often called the ‘silent killer’ because of the symptoms, which can be vague and easily mistaken for minor digestive issues. To date, we do not have a reliable tool to screen and detect ovarian cancer early.

Certain risk factors for ovarian cancer increase your chance of getting it in the future. An important point to keep in mind is that having a risk factor alone does not mean one will develop ovarian cancer in the future.

Conversely, some people who get ovarian cancer may not have any known risk factors. Some risk factors, like smoking, can be changed.

Others, like genetic mutations or family history, can’t be changed. Scientists have discovered several risk factors that increase a person’s chance of developing epithelial ovarian cancer.

These include:

Older age: Most ovarian cancers begin after menopause. If one experiences pelvic bleeding after menopause, it is important to see a doctor.

Genetics: Ovarian cancer does run in families. The most common inherited gene mutations are BRCA1 and BRCA2. We now have very reliable tests to detect these genetic mutations and tailor-made specific treatments which are effective.

Hormones: Hormones play a complex role in the development of ovarian cancer. In general, the total number of times a woman ovulates during her lifetime is related to her risk of ovarian cancer. More ovulations can mean a higher risk. Thus, early menses (before 12 years of age) or late menopause (after 52 years of age), and use of hormone replacement after menopause do increase your risk. Pregnancy and breastfeeding are considered protective.

Lifestyle: Certain factors such as lifestyle choices are within our control. While we cannot change our DNA or our reproductive history, certain lifestyle choices like smoking, drinking, and lack of exercise may influence our biological environment.

Weight Management: Research suggests a link between obesity and an increased risk of several cancers, including ovarian cancer. Adipose (fat) tissue produces estrogens, which can fuel certain cellular changes. Maintain a healthy weight to reduce your risk.

Sedentary Habits: Many studies suggest that regular exercise such as walking, yoga, and weight training can reduce your risk of ovarian cancer.

Smoking: While primarily linked to lung cancer, smoking is strongly associated with mucinous ovarian cancer, a specific subtype of the disease.

Dietary Patterns: While there is no singular “superfood” that can help prevent cancer, consuming a diet rich in vegetables, lots of lean proteins like fish, chicken, eggs, tofu, etc, and whole grains can help support a healthy immune system.

Every year, World Ovarian Cancer Day is observed on May 8. This is an initiative to raise awareness globally for educating the public about symptoms, risk factors, and the need for early detection of ovarian cancer. This year’s theme was No Woman Left Behind, which aims to ensure that all women have access to means of early detection, quality care, support, and to spread awareness so that no symptoms are ignored.

We should all do our bit but not spread fear or stigma. Since there is no universal screening tool for ovarian cancer, awareness of symptoms and associated risk factors is key. By recognizing the interplay between our genes, our hormonal history, and our daily habits, we can hope to move toward a future where ovarian cancer is detected earlier and treated more effectively.

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic and Mounjaro, are best known for treating type 2 diabetes and obesity. However, a new study published in The BMJ suggests that people with diabetes using these blockbuster drugs may have an increased risk of hair loss (alopecia).

While the absolute risk is low, researchers from the University of Pennsylvania and the University of Southern California identified alopecia as a possible side effect of GLP-1 receptor agonists, particularly semaglutide and tirzepatide.

“GLP-1 receptor agonist use was associated with a higher risk of clinically recorded alopecia, particularly non-scarring alopecia, in patients with type 2 diabetes, compared with SGLT-2 and DPP-4 inhibitors,” the researchers wrote.

Non-scarring alopecia is a type of hair loss in which the hair follicles remain intact, making hair regrowth possible.

The researchers said the findings could help inform shared decision-making when considering GLP-1 receptor agonist therapy and highlight the need for further research into dermatological outcomes.

What Did The Study Find?

Researchers analyzed health data from 12,004 patients using GLP-1 receptor agonists and compared them with 15,221 patients using SGLT-2 inhibitors between January 2019 and September 2024. They also compared another 11,964 GLP-1 receptor agonist users with 11,233 DPP-4 inhibitor users.

The study found that adults using GLP-1 receptor agonists had:

• A 37% higher risk of alopecia than SGLT-2 inhibitor users (6.91 vs. 5.04 per 1,000 person-years).
• A 68% higher risk of alopecia than DPP-4 inhibitor users (6.53 vs. 3.89 per 1,000 person-years).

Further analyses showed the association was specific to non-scarring alopecia, with a 53% higher risk compared with SGLT-2 inhibitors and a 72% higher risk compared with DPP-4 inhibitors.

Why GLP-1 Drugs Are Linked to Hair Loss?

The researchers noted that rapid weight loss is a well-established trigger of hair shedding and may also lead to iron or zinc deficiencies, disrupting the hair growth cycle.

They added that hormonal changes may also play a role, although further studies are needed to understand the underlying mechanisms.

What Are the Study's Limitations?

The researchers acknowledged that they could not assess the severity, extent, duration, or reversibility of alopecia after treatment was stopped because of limited clinical information. They also could not rule out the influence of other unmeasured factors.

However, they said the study was based on high-quality data from a large, representative cohort, and the findings remained consistent across additional analyses.

“Our findings extend previous anecdotal safety signals and provide more systematic evidence to inform clinical awareness of this potential adverse effect,” the researchers concluded.

What To Do If You're Losing Hair on Ozempic, Mounjaro?

If you're experiencing excessive hair shedding while taking semaglutide, you may consider:

• Discussing with your physician whether your dosage should be adjusted or whether nutritional supplements may help.
• Increasing your protein intake to at least 100 grams per day.
• Taking hair-supporting nutrients such as biotin, vitamin D, iron, and zinc.
• Using topical treatments such as minoxidil to support hair regrowth.
• Avoiding severe calorie restriction and maintaining a nutritionally balanced diet.

Between climbing the career ladder, raising kids, and keeping everything else running smoothly, there's rarely a spare moment when women should stop and check in with their own bodies.

Yet these same demanding years are often when certain autoimmune and chronic conditions first start to surface. The early signs tend to be so mild and easy to explain away that most women simply put them down to stress, lack of sleep, or an overly full plate.

Some of the autoimmune conditions that commonly fly under the radar include:

· Lupus

· Rheumatoid arthritis

· Sjogren’s syndrome

· Systemic sclerosis

· Psoriatic arthritis

Family history matters more than most women realize. Autoimmune conditions often have a genetic component, and having a parent, sibling, or close relative with an autoimmune disorder meaningfully raises the likelihood of developing one yourself, even if the specific condition isn't identical. If this applies to a woman, the symptoms below deserve even closer attention and a lower threshold for seeking medical advice, rather than waiting to see if they resolve on their own.

So, when should women get it checked? If any of these symptoms stick around rather than passing after a good night's sleep, it's worth paying attention:

· Fatigue that doesn't go away no matter how much rest you get

· Joint pain or stiffness, especially in the morning

· Unexplained aches in your muscles

· Skin rashes or a new sensitivity to sunlight

· Sudden shifts in your weight or energy levels

It is advised not to dismiss them, particularly if they've been going on for a few weeks. Early detection changes everything. It is observed that the difference between a manageable condition and a complicated one often comes down to how soon it was caught.

Diagnose early, and treatment can be initiated before the disease has a chance to progress, allowing a patient to continue living life on her own terms, not one dictated by illness.

That said, the fundamentals of good health have never changed, and we continue to emphasize routine check-ups, a balanced diet, adequate sleep, regular physical activity, and sound stress management. But if there is one thing every woman should take seriously, it is to learn to listen to your own body.

You know it better than anyone else. If something feels different, do not dismiss it or wait it out; seek an opinion. Awareness combined with timely action is what ultimately allows a woman to lead a full, active life both professionally and personally, well into her later years.

(Dr. Chirag Rajkumar Kopp, Consultant - Rheumatology & Clinical Immunology, Ramaiah Memorial Hospital, Bengaluru)